Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWI iShares MSCI Italy ETF	$51.53 -0.3%	$48.69	$35.20 ▼ $51.92	$757.49M	1.03	467,876 shs	1.26 million shs
PEY Invesco High Yield Equity Dividend Achievers ETF	$21.07 -0.3%	$20.85	$18.32 ▼ $23.22	$1.13B	0.87	191,614 shs	211,852 shs
SLS SELLAS Life Sciences Group	$1.76 -4.9%	$1.78	$0.77 ▼ $2.27	$194.80M	2.26	1.79 million shs	1.70 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWI iShares MSCI Italy ETF	+0.14%	+1.15%	+7.62%	+8.73%	+37.95%
PEY Invesco High Yield Equity Dividend Achievers ETF	-0.28%	-0.98%	+0.81%	+5.28%	-0.24%
SLS SELLAS Life Sciences Group	+8.82%	+19.74%	0.00%	+5.11%	+41.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWI iShares MSCI Italy ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	2.845 of 5 stars	3.5	2.0	0.0	0.0	3.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWI iShares MSCI Italy ETF	0.00	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	2.30	Hold	$21.07	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	297.73% Upside

Current Analyst Ratings Breakdown

Latest CLIG, SLS, PEY, and EWI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWI iShares MSCI Italy ETF	N/A	N/A	N/A	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	$1M	185.33	N/A	N/A	$0.25 per share	7.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWI iShares MSCI Italy ETF	N/A	N/A	12.30	∞	N/A	N/A	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A	N/A	13.11	∞	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	0.00	N/A	N/A	N/A	-132.51%	-92.79%	N/A

Latest CLIG, SLS, PEY, and EWI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWI iShares MSCI Italy ETF	$1.38	2.68%	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	$0.95	4.51%	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Latest CLIG, SLS, PEY, and EWI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/18/2025	PEY Invesco High Yield Equity Dividend Achievers ETF	Monthly	$0.0809	4.62%	8/18/2025	8/18/2025	8/22/2025
7/21/2025	PEY Invesco High Yield Equity Dividend Achievers ETF		$0.0875		7/21/2025	7/21/2025	7/25/2025
6/23/2025	PEY Invesco High Yield Equity Dividend Achievers ETF	Monthly	$0.0864	5.12%	6/23/2025	6/23/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWI iShares MSCI Italy ETF	N/A	N/A	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	4.91	4.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWI iShares MSCI Italy ETF	37.96%
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
EWI iShares MSCI Italy ETF	N/A
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWI iShares MSCI Italy ETF	N/A	14.70 million	N/A	Not Optionable
PEY Invesco High Yield Equity Dividend Achievers ETF	N/A	53.53 million	N/A	Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	103.82 million	Not Optionable

CLIG, SLS, PEY, and EWI Headlines

Recent News About These Companies

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

August 20 at 11:47 AM | marketbeat.com

SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)

August 20 at 3:09 AM | americanbankingnews.com

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

August 19 at 10:09 PM | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings Results

August 14, 2025 | marketbeat.com

Sellas Life Sciences Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

August 12, 2025 | msn.com

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

August 9, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLIG, SLS, PEY, and EWI Company Descriptions

iShares MSCI Italy ETF NYSEARCA:EWI

$51.53 -0.16 (-0.31%)

Closing price 04:10 PM Eastern

Extended Trading

$51.53 0.00 (0.00%)

As of 07:27 PM Eastern

iShares MSCI Italy Capped ETF, formerly iShares MSCI Italy Capped Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI Italy 25/50 Index (Index). The Index consists of stocks traded primarily on the Milan Stock Exchange. The Underlying Index is a free-float adjusted market capitalization weighted index with a capping methodology applied to issuer weights so that no single issuer of a component exceeds 25% of the Underlying Index weight and all issuers with weight above 5% do not exceed 50% of the Underlying Index weight. Components primarily include energy, financial and utilities companies. The Fund will at all times invest at least 80% of its assets in the securities of its Underlying Index and in depositary receipts (DRs) representing securities in its Underlying Index. The Fund's investment advisor is BlackRock Fund Advisors.

Invesco High Yield Equity Dividend Achievers ETF NASDAQ:PEY

$21.07 -0.07 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$21.14 +0.07 (+0.33%)

As of 06:01 PM Eastern

PowerShares High Yield Equity Dividend Achiever Portfolio (the Fund) is based on the Mergent Dividend Achiever 50 Index (the Index). The Fund focuses to invest at least 90% of its total assets in dividend paying common stocks, which comprise the Index. The Index is comprised of 50 stocks selected principally on the basis of dividend yield and consistent growth in dividends. The Funds sector allocation includes consumers discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, materials and telecommunication services. Invesco PowerShares Capital Management LLC serves as investment adviser the Fund.

SELLAS Life Sciences Group NASDAQ:SLS

$1.76 -0.09 (-4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.23%)

As of 08:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time